Clinical Trials Logo

Citation(s)

  •   Plotkin H, Gundberg C, Mitnick M, Stewart AF
    Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1-36) in humans: potential as an anabolic therapy for osteoporosis. J Clin Endocrinol Metab. 1998 Aug;83(8):2786-91.
  •   Stewart AF, Cain RL, Burr DB, Jacob D, Turner CH, Hock JM
    Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893. J Bone Miner Res. 2000 Aug;15(8):1517-25.
  •   Syed MA, Horwitz MJ, Tedesco MB, Garcia-OcaƱa A, Wisniewski SR, Stewart AF
    Parathyroid hormone-related protein-(1--36) stimulates renal tubular calcium reabsorption in normal human volunteers: implications for the pathogenesis of humoral hypercalcemia of malignancy. J Clin Endocrinol Metab. 2001 Apr;86(4):1525-31.

Pathophysiology of PTH-related Protein in Humans.

Details for clinical trial NCT00021827